


Electronic supplementary material



ESM Fig. 2 Change in weight (LS mean \pm SEM) from baseline to endpoint (ITT population).

There were 500 and 503 patients with evaluable weight data in the NPH insulin and insulin glargine groups, respectively. The difference in progression rate between treatment groups was -1.2 (95% CI $-2.34, 0.00$). BID, twice daily; QD, once daily